On June 24, Illumina completed the divestiture of Grail, which will now operate independently and list its shares on the Nasdaq Stock Exchange under the ticker $GRAL. Grail, a cancer diagnostic test maker, aims to launch a multi-cancer blood test but faces numerous challenges as it debuts on Nasdaq. Despite high hopes for its flagship cancer test, Grail's shares fell by as much as 11.7% in their market debut. The company is betting on commercial partnerships with health systems, employers, and life sciences companies to drive its success. This marks the 'Final Resolution' of a decade of drama surrounding the acquisition.
Bay Area early cancer detection company Grail goes public after spinning out from Illumina — again https://t.co/3mi9ytjxpC
Shares of Grail fell as much as 11.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina . https://t.co/cXMfpNrut5 https://t.co/cXMfpNrut5
Illumina spinoff Grail going public today on the Nasdaq. Grail CEO joined us ahead of the opening trade to talk early cancer detection and its testing products. https://t.co/dbTCy5ynJU
$GRAL Grail to begin trading as $ILMN Illumina completes spinoff - SA https://t.co/jdSnW4GjbQ
Listing today on @NasdaqExchange, @GrailBio is focused on reducing the global burden of cancer through innovative multi-cancer screening technologies. Congratulations, $GRAL team! https://t.co/YW6KZWGCf6
Illumina parts ways with Grail, with divestiture complete https://t.co/KjRqohmXgk #biotech #news
Grail prepares for public debut, and challenges of going independent, after spinoff from Illumina https://t.co/VIR3rdcrQ8 #news #biotech
STAT+: Grail, aiming to launch a blood test for cancer, faces host of challenges as it debuts on Nasdaq https://t.co/w4xGz1ont6 #news #biotech
Illumina completes the divestiture of GRAIL https://t.co/el5WhALGdP #news #biotech
GRAIL to Begin Trading on the Nasdaq Stock Exchange $GRAL https://t.co/k5P6CcqwZ8
Grail bets big on flagship cancer test after spin-off from Illumina https://t.co/GJefz4qK8y https://t.co/GJefz4qK8y
🔵 GRAIL BETS BIG ON FLAGSHIP CANCER TEST AFTER SPIN-OFF FROM ILLUMINA U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina, is betting that commercial partnerships with health systems, employers and life…
Grail, aiming to launch a blood test for cancer, faces host of challenges as it debuts on Nasdaq https://t.co/vf6aiEZm0x via @matthewherper for @statnews
#News After a decade of drama, Grail goes public with high hopes for its multi-cancer blood test but also many issues yet to settle. https://t.co/UAk1JkXk78
Grail, aiming to launch a blood test for cancer, faces host of challenges as it debuts on Nasdaq https://t.co/Bx4p8lGtCy
Illumina completes the divestiture of GRAIL $ILMN https://t.co/dSJ36iVPzB
StockWatch: "Final Resolution" Set for Illumina's Grail Saga Illumina’s long saga over its acquisition of Grail will end this week, when the sequencing giant spins off the cancer blood test developer. Read more: https://t.co/7vT9ckjjCu https://t.co/wgUoCXF8kI
21June: On the eve of @illumina's spinoff of @GrailBio, how have shares of $ILMN and $GRALV fared this week? And what have analysts said? Read about both companies plus updates on $AVTE, $GOVX, $MBIO, $OVID, and $SRPT in my latest StockWatch for @GENbio: https://t.co/H7NpnIBOwH
Grail https://t.co/yC5cBexshy